Preventive interventions should be offered only to patients whose life expectancy exceeds that of the intervention s time to benefit - if that time interval is known. In this metaanalysis, researchers determined the time to benefit after starting statins for preventing a first major adverse cardiovasc...
Introduction: Statins are beneficial for both primary and secondary prevention of cardiovascular disease in many patients at elevated risk. However, selection of patients most likely to respond and least likely to have adverse effects can benefit from refinement. While pharmacogenomic aspects of statins ...
Conclusion: Most ACS patients were prescribed antiplatelets, and statins, but the use of ACEIs or ARBs was suboptimal. Strategies are needed to enhance ACEI or ARB prescribing, especially for high risk patients who would have the greatest therapeutic benefit from these drugs. 展开 ...
The benefit of cholesterol-lowering therapy in the prevention of coronary heart disease (CHD) is well established. The secondary prevention Scandinavian Si... AM Gotto,SM Grundy - 《Circulation》 被引量: 196发表: 1999年 Low-density lipoprotein cholesterol in patients with stable coronary heart dis...
lipoproteins may provide additional information in risk stratification.(1) In particular, persistently elevated measures of low-density lipoprotein (LDL) particles, in patients whose LDL-cholesterol (C) appears optimally controlled, may identify individuals more likely to benefit from more intensive lipid...
Likewise, the numerical reduction of high-sensitivity troponin, high-sensitivity CRP and insulin resistance score, seen in the presented data, should be explored in subsequent larger studies to evaluate any potential benefit on CV risk by reducing subclinical cardiac muscle damage, metabolic ...
When applying trial-estimated statin benefit via introducing a trial-estimated relative risk reduction to each annual transition probability29 (“Methods”, Eq. (6)) under MSGene lifetime projections, predicted absolute risk under treatment for the same high genetic risk male at age 40 improves ...
The incremental net-benefit of statin therapy was positive for values of willingness to pay (WTP) equal or greater than €0. The probability that statin therapy was cost-effective was 50% for WTP equal to €0 and about 75% for values equal or greater than €250. Medication adherence ...
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. 喜欢 0 阅读量: 35 摘要: Long-term administration of statin therapy has been shown to reduce major coronary events and cardiac mortality within randomized clinical trials. In addition ...
We used independent sample t-tests, one-way ANOVA, and chi-square statistics to examine differences by race/ethnicity, statin medication use, and diabetes status. 2.3.1. Conceptual Model We constructed the directed acyclic graph (DAG) shown in Figure 1 based on an extensive literature review, ...